Clinical study of subretinal transplantation of human embryo stem cell derived retinal pigment epitheliums in treatment of macular degeneration diseases

General Information

Summary The purpose of this study was to determine the safety and therapeutic effect of sub-retinal transplantation of human embryo stem cell derived retinal pigment epitheliums (hESC-RPE) in patients with macular degeneration diseases, and explore new treatment modalities for macular degeneration diseases (Age-related macular degeneration and Stargardt's macular dystrophy).
Clinical trials phase Phases 1/2
Start date (estimated) 2015-05-01
End date (estimated) 2019-12-31
Clinical feature
Label Macular Degeneration
Link http://purl.obolibrary.org/obo/NCIT_C123330
Description Loss of vision in the central portion of the retina (macula), secondary to retinal degeneration.
Publications

Administrative Information

NCT number NCT02749734
ICTRP weblink http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-OCB-15006423
Other study identifiers
Name ChiCTR-OCB-15006423
Name 2013CB967002
Source weblink https://clinicaltrials.gov/ct2/show/NCT02749734
Regulatory body approval
Country
Public contact
Email qinzyin@aliyun.com
Public email qinzyin@aliyun.com
First name Zheng
Last name Qin Yin
Phone +86 023 68754401
Country
China
Sponsors Chinese Academy of Sciences
Southwest Hospital, China

Cell Line

Recruitment

Recruitment Status Active, not recruiting
Estimated number of participants 9
Contact institutions/departments